What is the incidence of heart failure with preserved ejection fraction (HFpEF) versus heart failure with reduced ejection fraction (HFrEF) in breast cancer survivors compared to non-cancer controls?

Clicks: 4
ID: 323522
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #39 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Breast cancer survivors face elevated cardiovascular risks, yet the differential burden of heart failure with preserved ejection fraction (HFpEF) versus heart failure with reduced ejection fraction (HFrEF) remains poorly characterized. Understanding these heart failure phenotypes is crucial for optimizing cardio-oncology care and risk stratification in this vulnerable population. Methods This retrospective cohort study analyzed data from the National Inpatient Sample (2016-2022), including 23,387,119 adult female hospitalizations. Women with breast cancer (active diagnosis or history; n=5,000,103 weighted) were compared to controls without breast cancer (n=111,935,438 weighted). Heart failure subtypes were identified using ICD-10 codes, and outcomes were assessed using survey-weighted logistic regression adjusted for age, race, hypertension, diabetes, obesity, coronary artery disease, chronic kidney disease, smoking, hyperlipidemia, chronic obstructive pulmonary disease, anemia, and Charlson Comorbidity Index. Results Breast cancer patients were older (mean age 70.9 vs. 54.9 years, p<0.001) and had higher comorbidity burden (mean Charlson score 3.14 vs. 1.62, p<0.001). HFpEF prevalence was significantly higher in breast cancer patients compared to controls (10.16% vs. 7.23%, p<0.001), with an unadjusted odds ratio (OR) of 1.45 (95% CI: 1.44-1.47). HFrEF prevalence was similarly elevated (4.73% vs. 3.20%, p<0.001; unadjusted OR 1.50, 95% CI: 1.49-1.52). Overall heart failure prevalence reached 14.87% in breast cancer patients versus 10.41% in controls (p<0.001). In-hospital mortality was significantly higher among breast cancer patients (3.13% vs. 2.11%, p<0.001; unadjusted OR 1.50, 95% CI: 1.48-1.52). Among breast cancer patients, those with heart failure demonstrated increased mortality compared to those without heart failure (4.03% vs. 2.97%, p<0.001). Breast cancer patients experienced higher rates of atrial fibrillation (20.83% vs. 12.52%, p<0.001), acute kidney injury (16.64% vs. 12.98%, p<0.001), and sepsis (9.39% vs. 7.89%, p<0.001). Mean length of stay was longer for breast cancer patients (4.82 vs. 4.54 days, p<0.001), with progressive increases observed across heart failure phenotypes: 4.67 days (no HF), 5.71 days (HFpEF), and 5.65 days (HFrEF). Conclusions Breast cancer patients exhibit substantially elevated risks of both HFpEF and HFrEF, with HFpEF demonstrating the highest prevalence. These findings show the critical need for cardiovascular surveillance in breast cancer care, particularly for heart failure prevention and early detection. The disproportionate burden of HFpEF emphasizes the importance of disease-specific management strategies in cardio-oncology practice.
Reference Key
openalex_W7172253839 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors A Bolad, I Motairek, M Elganainy, F Alenezi, I Bolad
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.144
URL
https://doi.org/10.1093/eurheartjsupp/suag097.144
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.